Asia Pacific Brain Cancer Diagnostics Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, and Others); Cancer Type (Acoustic Neuroma, Astrocytoma, Craniopharyngiomas, Ganglioneuromas, Glioblastoma Multiforme, Meningiomas, Ependymomas, and Others); End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others)


No. of Pages: 159    |    Report Code: TIPRE00025896    |    Category: Life Sciences

Asia Pacific Brain Cancer Diagnostics Market
Buy Now

Market Introduction

Brain cancers are caused due to extracellular growth of the cells in the brain that causes tumors. The tumor includes primary brain tumors and secondary brain tumors. Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body.  Brain tumors are categorized into 40 major types that are further classified into two major groups, including benign, i.e., slow-growing and have less possibility to spread, and malignant, i.e., cancerous, and more likely to spread.

Thus, the increase in prevalence of brain cancer is expected to create a significant demand for brain cancer diagnostics in the coming years, which is further anticipated to drive the brain cancer diagnostics market.

The outbreak has severely affected the medical tourism industry in Asia pacific and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure, restrictions imposed by hospitals to the suppliers, decreasing in demand of brain cancer diagnostics devices and others. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent the disease transmission. These restrictive measures are anticipated to impact the supply chain and the availability of medical devices in these countries. It has affected disposable incomes and has also resulted in unemployment. Furthermore, business strategies such as acquisitions, mergers, and partnerships are adversely affected by the imposition of complete lockdown. Such obstructions in business activities are projected to hamper the adoption of various technologically advanced healthcare systems, including brain cancer diagnostics.

 


Get more information on this report

Asia Pacific Brain Cancer Diagnostics Strategic Insights

Strategic insights for the Asia Pacific Brain Cancer Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/asia-pacific-brain-cancer-diagnostics-market-strategic-framework.webp
Get more information on this report

Asia Pacific Brain Cancer Diagnostics Report Scope

Report Attribute Details
Market size in 2021 US$ 178.6 Million
Market Size by 2028 US$ 551.4 Million
Global CAGR (2021 - 2028) 17.5%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Diagnostic Type
  • Imaging Test
  • Lumbar Puncture
  • Biopsy
  • Molecular Testing
By Cancer Type
  • Acoustic Neuroma
  • Astrocytoma
  • Craniopharyngiomas
  • Ganglioneuromas
  • Glioblastoma Multiforme
  • Meningiomas
  • Ependymomas
By End User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
Regions and Countries Covered Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
Market leaders and key company profiles
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers A
  • GE Healthcare
  • Biocept, Inc.
  • Koninklijke Philips N.V
  • Canon Medical Systems
  • Hitachi, Ltd.
  • Neusoft Medical Systems
  • Get more information on this report

    Asia Pacific Brain Cancer Diagnostics Regional Insights

    The geographic scope of the Asia Pacific Brain Cancer Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/asia-pacific-brain-cancer-diagnostics-market-geography.webp
    Get more information on this report


    Market Overview and Dynamics

    The Brain cancer diagnostics market in Asia Pacific is expected to grow from US$ 178.6 million in 2021 to US$ 551.4 million by 2028; it is estimated to grow at a CAGR of 17.5% from 2021 to 2028. The term "primary brain tumor" refers to a tumor that begins in the brain. Cancer of the brain and nervous system is the tenth highest cause of mortality in men and women. In a person's lifetime, the chances of having this form of tumor are fewer than 1%. Most primary central nervous system (CNS) malignancies are brain tumors, which account for 85% to 90% of all cases. Brain tumors can be fatal, have a severe impact on quality of life, and ultimately transform a patient's and their family's lives.  Furthermore, early detection of tumors often provides more treatment options. Advanced imaging technology can pinpoint the location of brain tumors. Diagnostic tools include magnetic resonance imaging (MRI) and computed tomography (CT or CAT scan). Intraoperative MRI can also be used to guide tissue biopsy and tumor resection during surgery. Magnetic resonance spectroscopy (MRS) is used to examine the chemical characteristics of tumors. Thus, the increase in the prevalence of brain cancer highly demands brain cancer diagnostic tools.      

     

    Key Market Segments

    In terms of diagnostic type, the imaging test segment accounted for the largest share of the Asia Pacific brain cancer diagnostics market in 2020. In terms of cancer type, the glioblastoma multiforme segment accounted for the largest share of the Asia Pacific brain cancer diagnostics market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the Asia Pacific brain cancer diagnostics market in 2020.

     

    Major Sources and Companies Listed

    A few major primary and secondary sources referred to for preparing this report on the brain cancer diagnostics market in Asia Pacific are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Thermo Fisher Scientific Inc., Siemens Healthineers A, GE Healthcare, Biocept, Inc., Koninklijke Philips N.V, Canon Medical Systems, Hitachi, Ltd., and Neusoft Medical Systems.

     

    Reasons to buy report

    • To understand the Asia Pacific Brain cancer diagnostics market landscape and identify market segments that are most likely to guarantee a strong return
    • Stay ahead of the race by comprehending the ever-changing competitive landscape for Asia Pacific Brain cancer diagnostics market
    • Efficiently plan M&A and partnership deals in Asia Pacific Brain cancer diagnostics market by identifying market segments with the most promising probable sales
    • Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Asia Pacific Brain cancer diagnostics market
    • Obtain market revenue forecast for market by various segments from 2021-2028 in Asia Pacific region.

     

    Asia Pacific Brain Cancer Diagnostics Market Segmentation       

     

    By Diagnostic Type

    • Imaging Test
      • MRI
      • CT Scan
      • PET
    • Biopsy
    • Molecular Testing
    • Lumbar Puncture
    • Others

     

    By Cancer Type

    • Glioblastoma Multiforme
    • Astrocytomas
    • Ependymomas
    • Others

     

    By End User

    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Others

     

    By Country

    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia Pacific

     

    Companies Mentioned

    1. Thermo Fisher Scientific Inc.
    2. Siemens Healthineers A
    3. GE Healthcare
    4. Biocept, Inc.
    5. Koninklijke Philips N.V
    6. Canon Medical Systems
    7. Hitachi, Ltd.
    8. Neusoft Medical Systems

     

     

     

    The List of Companies - Asia Pacific Brain Cancer Diagnostics Market

    1. Thermo Fisher Scientific Inc.
    2. Siemens Healthineers A
    3. GE Healthcare
    4. Biocept, Inc.
    5. Koninklijke Philips N.V
    6. Canon Medical Systems
    7. Hitachi, Ltd.
    8. Neusoft Medical Systems
    Frequently Asked Questions
    How big is the Asia Pacific Brain Cancer Diagnostics Market?

    The Asia Pacific Brain Cancer Diagnostics Market is valued at US$ 178.6 Million in 2021, it is projected to reach US$ 551.4 Million by 2028.

    What is the CAGR for Asia Pacific Brain Cancer Diagnostics Market by (2021 - 2028)?

    As per our report Asia Pacific Brain Cancer Diagnostics Market, the market size is valued at US$ 178.6 Million in 2021, projecting it to reach US$ 551.4 Million by 2028. This translates to a CAGR of approximately 17.5% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Brain Cancer Diagnostics Market report typically cover these key segments-

    • Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing)
    • Cancer Type (Acoustic Neuroma, Astrocytoma, Craniopharyngiomas, Ganglioneuromas, Glioblastoma Multiforme, Meningiomas, Ependymomas)
    • End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers)

    What is the historic period, base year, and forecast period taken for Asia Pacific Brain Cancer Diagnostics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Brain Cancer Diagnostics Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Asia Pacific Brain Cancer Diagnostics Market?

    The Asia Pacific Brain Cancer Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers A
  • GE Healthcare
  • Biocept, Inc.
  • Koninklijke Philips N.V
  • Canon Medical Systems
  • Hitachi, Ltd.
  • Neusoft Medical Systems
  • Who should buy this report?

    The Asia Pacific Brain Cancer Diagnostics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Brain Cancer Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now